A Claudin-Targeting Peptide As a Potential Therapeutic for Ovarian Cancer
Heidi Wilson
Assistant Professor, Claudin Technologies and University of Colorado Denver -Anschutz Medical Campus
Heidi K. Baumgartner Wilson (1,3), Robert Hodges (2), Ginny Orndorff (3), and Margaret C. Neville (1,3)
(1) Department of Obstetrics & Gynecology and (2) Department of Biochemistry & Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA; (3) Claudin Technologies LLC, Aurora CO, USA.
Claudin-4 is a protein frequently overexpressed on the surface of tumors of epithelial origin, including the majority of ovarian tumors as well as cells thought to represent ovarian cancer stem cells. Claudin Technologies is developing a unique claudin mimic peptide (CMP) that significantly disrupts the activity of claudin-4 by binding to the surface of tumor cells, resulting in reduced tumor cell motility and increased cell death by apoptosis12-17. CMP is made of D-amino acids, making it resistant to proteolytic degradation. Injection of CMP into the peritoneal cavity of nude mice bearing human PEO4 ovarian tumors significantly reduced the rate of tumor progression and tumor cell apoptosis was increased 20-fold. CMP also induced apoptosis in human ovarian tumor slices freshly isolated from the operating room. Preliminary toxicity studies in mice show that doses of CMP injected IP or IV at 4 to 16 times the effective dose do not have detectable toxicities. The stability and preliminary safety and efficacy profiles of CMP suggest that it has promise as a therapeutic agent in ovarian cancer. Such targeted cancer therapies, used in appropriately selected patients, have the potential to significantly improve overall survival while avoiding unnecessary drug toxicity.
The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.
The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.
The Boulder Peptide Symposium offers multiple opportunities for participants to present.
The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.
Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.
Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.
Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.
Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.
Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.
Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.
The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.
Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.
Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.
A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.
Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.
Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.